About Us
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
Ibrexafungerp
Life-threatening Infections
Community Infections
Pipeline
Publications and Presentations
Product
News
News
Events
Careers
Investors
Ibrexafungerp
Life-threatening Infections
Invasive Fungal Infections
Invasive Candidiasis
Invasive Aspergillosis
Community Infections
Vulvovaginal Candidiasis
Recurrent VVC
Pipeline
Publications and Presentations
Our Science
Publications and Presentations
Date
Title
April 2023
Outcomes of Oral Ibrexafungerp in Subjects with Urinary Tract Infections from Two Phase 3 Open Label Studies: Difficult to Treat Invasive Fungal Infections (FURI) and Infections with Candida auris (CARES)
ECCMID, April 2023
April 2023
FURI Study: Outcomes in Subjects with Intraabdominal Candidiasis Treated with Oral Ibrexafungerp
ECCMID, April 2023
April 2023
A Novel Protocol Design to Study the Efficacy and Safety of Oral Ibrexafungerp as Step Down Therapy following Intravenous (IV) Echinocandin for the Treatment of Invasive Candidiasis (MARIO): Developing a Paradigm Shift to IV and Oral Anti-Cell Wall Therapy
ECCMID, April 2023
October 2022
All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Ibrexafungerp Open-label Study (FURI)
IDWeek
September 2022
Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
ISHAM
September 2022
Outcomes of Oral Ibrexafungerp in Refractory Patients with Candida from an Interim Analysis of a Phase 3 Open-Label Study (FURI)
MSGERC
September 2022
Outcomes of Oral Ibrexafungerp in the Treatment of 18 Patients with Candida auris Infections, from the CARES Study
MSGERC
September 2022
CANDLE: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Once Monthly Oral Ibrexafungerp for Prevention of Recurrent Vulvovaginal Candidiasis (VVC)
NPWH
September 2022
All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Ibrexafungerp Open-label Study (FURI)
ISHAM
June 2022
Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
< Prev
Next >
Please ensure Javascript is enabled for purposes of
website accessibility